"No evidence of X", according to the leading experts and politicians.
COVID-19 News and Discussions
Re: COVID-19 News and Discussions
And, as always, bye bye.
-
- Posts: 13532
- Joined: Sun May 16, 2021 6:16 pm
Re: COVID-19 News and Discussions
Mainland China reports 12,660 COVID-19 deaths in week as Lunar New Year begins
Source: United Press International
Read more: https://www.upi.com/Top_News/World-News ... 674398798/
Source: United Press International
.Mainland China rang in the Lunar New Year with large family gatherings and big public celebrations without the strict "zero-Covid" policy, despite a surge in cases and deaths, including 12,660 in the past week
Read more: https://www.upi.com/Top_News/World-News ... 674398798/
Re: COVID-19 News and Discussions
To know is essentially the same as not knowing. The only thing that occurs is the rearrangement of atoms in your brain.
-
- Posts: 13532
- Joined: Sun May 16, 2021 6:16 pm
Re: COVID-19 News and Discussions
The Covid Pandemic Drives Pfizer's 2022 Revenue to a Record $100 Billion
Source: CNBC
Source: CNBC
Read more: https://www.cnbc.com/2023/01/31/the-cov ... llion.html
Pfizer sold $37.8 billion of its Covid vaccine last year, a small increase of 3% compared with 2021 as demand for the shots slowed. Sales of Paxlovid, however, surged to $18.9 billion in 2022, which was the first full year the antiviral pill was available. Pfizer expects its revenue to decline in 2023 by as much as 33% to a range of $67 billion to $71 billion as the world emerges from the pandemic and demand for its blockbuster Covid drugs slows.
The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer’s earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.
The vaccine accounted for $37.8 billion, up just 3% from 2021, of Pfizer’s total sales as demand for the shots slowed. But sales of its blockbuster antiviral treatment made up for that softening, surging to $18.9 billion in 2022, the first full year that Paxlovid was on the market.
Pfizer’s combined sales from its Covid vaccine and antiviral treatment generated more revenue last year than it had in total sales in 2019, before the pandemic became a global crisis that killed more than 6.8 million people and upended world markets. Those results won’t be repeated this year...
-
- Posts: 13532
- Joined: Sun May 16, 2021 6:16 pm
Re: COVID-19 News and Discussions
CA no longer pursuing COVID vaccine mandate for K-12 schools, public health department says
Source: ABC7 Eyewitness News
Source: ABC7 Eyewitness News
Read more: https://abc7.com/california-covid-vacci ... /12768012/SACRAMENTO, Calif. -- California won't make children get the coronavirus vaccine to attend schools.
The California Department of Public Health said Friday it is not exploring emergency rules to add the COVID-19 vaccine to the list of required school vaccinations.
That's a reversal from Democratic Gov. Gavin Newsom's 2021 announcement that the state would add the COVID-19 vaccine to its list of mandated vaccinations for kids to attend school. Last year, state officials delayed that requirement until at least the summer of 2023.
Now public health officials say they are no longer moving ahead with the effort as the state prepares to end its coronavirus emergency on Feb. 28.
Re: COVID-19 News and Discussions
Young people are more likely to die of heart attacks post-COVID, study finds. But why?
A recent study found that heart attacks in people ages 25 to 44 increased by 30% compared to the expected number over the first two years of the COVID-19 pandemic.
Feb. 9, 2023, 7:47 PM GMT / Source: TODAY
[...]
“Young people are obviously not really supposed to die of heart attack. They’re not really supposed to have heart attacks at all,” Dr. Susan Cheng, a cardiologist at Cedars Sinai and co-author of the study, told TODAY in a segment aired Feb. 9.
[...]
The reason for the relative rise in young people in particular is unclear, but one theory, Cheng said, is that the virus's impact on the cardiovascular system in some people may be due to an excessive immune system response and that young people are more likely to have stronger immune systems.
[...]
If you've been infected with COVID-19, especially multiple times, Cheng also encouraged staying on top of your risk factors for heart disease, such as your blood pressure, cholesterol and blood sugar.
[...]
Prior to the COVID-19 pandemic, heart attack deaths were trending downward in the United States, but the pandemic appears to have reversed the progress, according to the Cedars Sinai research.
"I'd love to say we're ... coming out on the other side and we can think of COVID more so like the common cold. Unfortunately, that is not the case. ... That is eminently clear from all of the data," Cheng said. "This is not even just like the flu. ... This virus is still very different from any other virus we have seen in our lifetime."
https://www.today.com/health/covid-hear ... -rcna69903
A recent study found that heart attacks in people ages 25 to 44 increased by 30% compared to the expected number over the first two years of the COVID-19 pandemic.
Feb. 9, 2023, 7:47 PM GMT / Source: TODAY
[...]
“Young people are obviously not really supposed to die of heart attack. They’re not really supposed to have heart attacks at all,” Dr. Susan Cheng, a cardiologist at Cedars Sinai and co-author of the study, told TODAY in a segment aired Feb. 9.
[...]
The reason for the relative rise in young people in particular is unclear, but one theory, Cheng said, is that the virus's impact on the cardiovascular system in some people may be due to an excessive immune system response and that young people are more likely to have stronger immune systems.
[...]
If you've been infected with COVID-19, especially multiple times, Cheng also encouraged staying on top of your risk factors for heart disease, such as your blood pressure, cholesterol and blood sugar.
[...]
Prior to the COVID-19 pandemic, heart attack deaths were trending downward in the United States, but the pandemic appears to have reversed the progress, according to the Cedars Sinai research.
"I'd love to say we're ... coming out on the other side and we can think of COVID more so like the common cold. Unfortunately, that is not the case. ... That is eminently clear from all of the data," Cheng said. "This is not even just like the flu. ... This virus is still very different from any other virus we have seen in our lifetime."
https://www.today.com/health/covid-hear ... -rcna69903
Re: COVID-19 News and Discussions
Comprehensive Study Provides Evidence on Natural Immunity Protection by COVID-19 Variant and How Protection Fades Over Time
February 16, 2023
Introduction:
For a technical presentation of the results of the study: https://www.thelancet.com/journals/lan ... /fulltect
February 16, 2023
Introduction:
Read more of the EurekAlert article here: https://www.eurekalert.org/news-releases/979806(EurekAlert)
• Largest review and meta-analysis assessing the extent of protection following COVID-19 infection by variant and how durable that protection is against different variants, including 65 studies from 19 countries.
• For people who have been infected with COVID-19 at least once before, natural immunity against severe disease (hospitalisation and death) was strong and long-lasting for all variants (88% or greater at 10 months post infection).
• Past infection with pre-Omicron variants provided substantially reduced natural immunity protection against reinfection with Omicron BA.1 (36% at 10 months after infection).
• The researchers say we should recognise the natural immunity in people who have recently been infected with COVID-19, but warn that their findings should not discourage vaccination because it is the safest way to acquire immunity.
For a technical presentation of the results of the study: https://www.thelancet.com/journals/lan ... /fulltect
Don't mourn, organize.
-Joe Hill
-Joe Hill
Re: COVID-19 News and Discussions
Higher ivermectin dose, longer duration still futile for COVID, trial finds
Mary Van Beusekom, MS
February 21, 2023
A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
In the double-blind trial, published yesterday in JAMA, a team led by Duke University researchers evaluated time to sustained recovery among 1,206 COVID-19 patients at 93 US sites from Feb 16 to Jul 22, 2022, with follow-up until Nov 10, 2022. Sustained recovery was considered at least 3 days without symptoms.
Patients were at least 30 years old and had two or more symptoms for no more than 7 days, 59.1% were women, and 83.5% reported receiving two or more COVID-19 vaccine doses.
The trial was part of the ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6), which was designed to assess the effectiveness of repurposed drugs such as ivermectin in the treatment of mild to moderate COVID-19.
https://www.cidrap.umn.edu/covid-19/hig ... rial-finds
Mary Van Beusekom, MS
February 21, 2023
A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
In the double-blind trial, published yesterday in JAMA, a team led by Duke University researchers evaluated time to sustained recovery among 1,206 COVID-19 patients at 93 US sites from Feb 16 to Jul 22, 2022, with follow-up until Nov 10, 2022. Sustained recovery was considered at least 3 days without symptoms.
Patients were at least 30 years old and had two or more symptoms for no more than 7 days, 59.1% were women, and 83.5% reported receiving two or more COVID-19 vaccine doses.
The trial was part of the ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6), which was designed to assess the effectiveness of repurposed drugs such as ivermectin in the treatment of mild to moderate COVID-19.
https://www.cidrap.umn.edu/covid-19/hig ... rial-finds